• sv
Contact
  • About us

    About us

    Orexo is a fully integrated specialty pharmaceutical company

     

    • CEO comments
    • Objectives & Strategies
    • Key market
    • Financial information
    • Board of Directors & Management
    • Corporate Governance
    • Career
    • Meet us
    • History
  • Key Therapeutic Area

    Key Therapeutic Area

    Opioid addiction is a treatable chronic disease

  • Products

    Products

    Developed 4 products approved worldwide

    • Zubsolv®
    • Abstral®
    • Edluar®
  • Pipeline

    Pipeline

    Embracing all aspects of opioid addiction

    • Innovation
    • Technologies
    • OX124 Opioid overdose
    • OX125 Opioid overdose
    • OX338 Acute moderate to severe pain
    • OX382 Opioid dependence
    • OX-MPI Microvasular disease
    • OXD01 Opioid Use Disorder
    • OXD02 Alcohol Use Disorder
  • Sustainability

    Sustainability

    We will be recognized for the added value our products bring to patients and societies

    • Our team
    • People and society
    • Opioidcrisis
    • Our commitments
  • Investors

    Investors

    Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.

    • Financial calendar & events
    • Press releases
    • News
    • Reports, presentations and audiocasts
    • Analysts
    • Subscription
    • The share
    • Value Drivers
    • Key market
    • Financial information & key figures
    • Prospectus
    • IR contact
  • Media

    Media

    Follow Orexo in social media

    • Press releases
    • News
    • Social media
    • Image bank
    • Press contact
Top image

A specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction

Read more

Dennis Urbaniak appointed EVP Digital Health

DECEMBER 2, 2019 - Orexo strengthen its competencies within digital health, by appointing Dennis Urbaniak as EVP for Digital Health. Dennis has had a long, successful career within the life sciences industry and during the last years become one of the leading experts in digital health in the US. At Orexo Dennis will have an instrumental role in the work to find innovative digital solutions to improve treatment of addiction.

Read the PR

Orexo acquires exclusive US rights to commercialize vorvida®

NOVEMBER 27, 2019 – In line with the ambition to become a leader within treatment of addiction the company today has extended its partnership with GAIA AG by in-licensing of the US commercial rights to vorvida®, a digital therapy for the treatment of Alcohol Use Disorder (AUD). Vorvida® is a fully automated digital therapy with significantly proven efficacy to reduce troublesome drinking patterns in adults with AUD.

Read the PR

Save the Date – Capital Markets Day focusing on Digital Health

Investors, analysts and media are invited to attend our Capital Markets Day that will take place at, Helio GT 30, Grev Turegatan 30, Stockholm, Sweden. The program will start at 1:30 pm CET, with registration from 1:00 pm CET. The event plans to end at 4.00 pm CET. A formal invitation with a complete program will be sent out at a later date. #strategy #pipeline #digitalhealth

For registration

Our CEO about entering Digital Therapies

AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.

Watch the video

October 24, 2019 - "Strong financials driving continued focus on new product opportunities and pipeline progression" 

 

Read the latest CEO comments from Nikolaj Sørensen
Read more
Shareprice
Orexo
62
-0.9 SEK (-1.43%)
05:29 CET • 13 Dec 2019
Financial calendar & events
  • J.P. Morgan 38th Annual Healthcare Conference
    Jan 13 2020
  • Full Year Report incl. Q4 2019
    Jan 30 2020
  • Carnegie Nordic Healthcare Seminar
    Mar 3 2020
Press releases
  • Orexo acquires exclusive US rights to commercialize vorvida®, a digital therapy for alcohol use disorder with scientifically proven efficacy
    Nov 27 2019
  • Orexo Interim Report Q3 2019
    Oct 24 2019
  • Orexo Interim Report Q2 2019
    Jul 11 2019
News
  • Save the date: Orexo to host Capital Markets Day focusing on Digital Health, on March 17, 2020
    Dec 3 2019
  • Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health
    Dec 2 2019
  • Orexo to Present at Jefferies 2019 Healthcare Conference
    Nov 8 2019

@OrexoABpubl

From last week - another great article covering Orexo’s #vorvida deal with @GAIA_COM by @MedtechCate at… https://t.co/b0VQfDty8N

@OrexoABpubl

Save the Date -> #orexo invites investors, analysts and media to a Capital Markets Day on March 17, 2020.… https://t.co/SHuJgma6fR

@OrexoABpubl

#orexo strengthen its competencies and resources within digital health by appointing Dennis Urbaniak, one of the le… https://t.co/KzxddJevde

Our drug delivery technologies improve pharmaceuticals

 

P.O. Box 303. SE-751 05 Uppsala, Sweden

Tel. +46 (0)18 780 88 00

info@orexo.com

 

©2019

Orexo AB (publ.) – All rights reserved

Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy Orexo US

This website intends to use cookies to improve the website and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information, Read more

Accept
Disclaimer
Return Continue